scholarly journals Dentinogenic Specificity in the Preclinical Evaluation of Vital Pulp Treatment Strategies: A Critical Review

2015 ◽  
Vol 3 (4) ◽  
pp. 133-156 ◽  
Author(s):  
Dimitrios Tziafas ◽  
Konstantinos Kodonas
2020 ◽  
Vol 35 ◽  
pp. 101232 ◽  
Author(s):  
Pallvi Bhanot ◽  
S. Mary Celin ◽  
T.R. Sreekrishnan ◽  
Anchita Kalsi ◽  
S.K. Sahai ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (11) ◽  
pp. e0225146
Author(s):  
Michele B. Daly ◽  
April M. Clayton ◽  
Susan Ruone ◽  
James Mitchell ◽  
Chuong Dinh ◽  
...  

2015 ◽  
Vol 6 ◽  
Author(s):  
Agathoklis D. Passos ◽  
Aikaterini A. Mouza ◽  
Spiros V. Paras ◽  
Christos Gogos ◽  
Dimitrios Tziafas

2003 ◽  
Vol 21 (11) ◽  
pp. 2199-2210 ◽  
Author(s):  
Simon Wilkinson ◽  
Gerald W. Chodak

Despite its prominence as the most frequently diagnosed solid tumor among men in the United States, relatively little is known about the etiology of prostate cancer. Furthermore, research into treatment strategies for prostate cancer continues to lag behind research for the other most common cancers. At the same time, however, the popularity of complementary therapies among prostate cancer patients continues to grow. In this article, we provide a critical review of the most recent evidence for dietary modifications, food supplements, and herbs in prostate cancer prevention and treatment. Despite encouraging data for some of these interventions, even the strongest proponents of complementary therapy agree that only randomized controlled trials can provide sufficient evidence on which to create universal guidelines. However, such trials are highly complex and expensive, and they require lengthy follow-up. Until such trials are completed, an opportunity exists for health care professionals to improve their knowledge and understanding of the current evidence for or against complementary therapy in prostate cancer.


2019 ◽  
Vol 160 ◽  
pp. 94-109 ◽  
Author(s):  
G. Janet Joshiba ◽  
P. Senthil Kumar ◽  
Carolin C. Femina ◽  
Eunice Jayashree ◽  
R. Racchana ◽  
...  

2021 ◽  
Vol 15 (11) ◽  
pp. e0009921
Author(s):  
Jesil Mathew Aranjani ◽  
Atulya Manuel ◽  
Habeeb Ibrahim Abdul Razack ◽  
Sam T. Mathew

Coronavirus Disease 2019 (COVID-19), during the second wave in early 2021, has caused devastating chaos in India. As daily infection rates rise alarmingly, the number of severe cases has increased dramatically. The country has encountered health infrastructure inadequacy and excessive demand for hospital beds, drugs, vaccines, and oxygen. Adding more burden to such a challenging situation, mucormycosis, an invasive fungal infection, has seen a sudden surge in patients with COVID-19. The rhino-orbital-cerebral form is the most common type observed. In particular, approximately three-fourths of them had diabetes as predisposing comorbidity and received corticosteroids to treat COVID-19. Possible mechanisms may involve immune and inflammatory processes. Diabetes, when coupled with COVID-19–induced systemic immune change, tends to cause decreased immunity and an increased risk of secondary infections. Since comprehensive data on this fatal opportunistic infection are evolving against the backdrop of a major pandemic, prevention strategies primarily involve managing comorbid conditions in high-risk groups. The recommended treatment strategies primarily included surgical debridement and antifungal therapy using Amphotericin B and selected azoles. Several India-centric clinical guidelines have emerged to rightly diagnose the infection, characterise the clinical presentation, understand the pathogenesis involved, and track the disease course. Code Mucor is the most comprehensive one, which proposes a simple but reliable staging system for the rhino-orbital-cerebral form. A staging system has recently been proposed, and a dedicated registry has been started. In this critical review, we extensively analyse recent evidence and guidance on COVID-19–associated mucormycosis in India.


Sign in / Sign up

Export Citation Format

Share Document